LTA4H (leukotriene A4 hydrolase) is a bifunctional zinc metalloenzyme that plays crucial roles in inflammation and immune regulation. Its primary function involves converting leukotriene A4 to the pro-inflammatory mediator leukotriene B4 (LTB4) through epoxide hydrolase activity, while also possessing aminopeptidase activity that can counteract inflammation 1. In cancer contexts, LTA4H demonstrates opposing roles: it is overexpressed in colorectal cancer where it promotes tumor progression and correlates with survival probability 1, while in hepatocellular carcinoma, LTA4H deficiency exacerbates disease progression by promoting immunosuppressive macrophage polarization through TGF-β signaling 2. LTA4H also contributes to cardiovascular pathology, where it regulates inflammatory cell migration and smooth muscle cell phenotype modulation in thoracic aortic dissection 3. Regarding infectious diseases, LTA4H genetic polymorphisms show population-specific associations with tuberculosis susceptibility, particularly affecting extrapulmonary tuberculosis in Han Chinese populations 4, though these associations are not consistent across all populations 5. Additionally, LTA4H variants contribute to drug response variability in asthma treatment, particularly affecting leukotriene modifier efficacy 6. The enzyme's dual pro- and anti-inflammatory functions make it a potential therapeutic target across multiple disease contexts.